- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Portsmouth Today
By the People, for the People
NovoCure Projected to Post Q4 2025 Earnings on Thursday
Analysts expect the medical device company to report a loss per share and $174.4 million in revenue.
Published on Feb. 25, 2026
Got story updates? Submit your updates here. ›
NovoCure (NASDAQ:NVCR), a global oncology company pioneering Tumor Treating Fields (TTFields) therapy, is expected to release its Q4 2025 financial results before the market opens on Thursday, February 26, 2026. Analysts project the company will report a loss of $0.40 per share and $174.4 million in revenue for the quarter.
Why it matters
NovoCure's quarterly earnings report will provide investors with the latest financial performance data and insights into the company's progress in commercializing its novel TTFields cancer therapy. As a leading innovator in the oncology space, NovoCure's results are closely watched by industry analysts and the medical community.
The details
NovoCure is a global oncology company that has pioneered Tumor Treating Fields (TTFields), a non-invasive therapy that uses low-intensity, alternating electric fields to disrupt cancer cell division. The company's Q4 2025 earnings report will detail its latest financial and operational performance as it continues to commercialize this novel cancer treatment approach.
- NovoCure is expected to release its Q4 2025 results before the market opens on Thursday, February 26, 2026.
- The company's earnings call is scheduled for 8:00 AM ET on Thursday, February 26, 2026.
The players
NovoCure
A global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors.
What’s next
Investors and analysts will be closely watching NovoCure's Q4 2025 earnings report for updates on the company's financial performance, commercial progress, and the ongoing development of its TTFields cancer therapy.
The takeaway
As a leader in the oncology space, NovoCure's quarterly earnings report will provide valuable insights into the company's ability to commercialize its innovative Tumor Treating Fields technology and drive growth in the hard-to-treat cancer market.
